WO2006033948A3 - Sustained local anesthetic composition containing preferably a sugar ester such as saib - Google Patents

Sustained local anesthetic composition containing preferably a sugar ester such as saib Download PDF

Info

Publication number
WO2006033948A3
WO2006033948A3 PCT/US2005/032863 US2005032863W WO2006033948A3 WO 2006033948 A3 WO2006033948 A3 WO 2006033948A3 US 2005032863 W US2005032863 W US 2005032863W WO 2006033948 A3 WO2006033948 A3 WO 2006033948A3
Authority
WO
WIPO (PCT)
Prior art keywords
anesthetic
compositions
sugar ester
saib
composition containing
Prior art date
Application number
PCT/US2005/032863
Other languages
French (fr)
Other versions
WO2006033948A2 (en
Inventor
Neil A Verity
Original Assignee
Durect Corp
Neil A Verity
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0515372A priority Critical patent/BRPI0515372B8/en
Priority to EP05812735A priority patent/EP1809329B1/en
Application filed by Durect Corp, Neil A Verity filed Critical Durect Corp
Priority to DK05812735.8T priority patent/DK1809329T3/en
Priority to CA2581287A priority patent/CA2581287C/en
Priority to ES05812735T priority patent/ES2378671T3/en
Priority to SI200531496T priority patent/SI1809329T1/en
Priority to KR1020137031550A priority patent/KR101492361B1/en
Priority to RS20120121A priority patent/RS52198B/en
Priority to US11/663,125 priority patent/US8753665B2/en
Priority to AT05812735T priority patent/ATE537844T1/en
Priority to AU2005287175A priority patent/AU2005287175B2/en
Priority to MX2007002962A priority patent/MX2007002962A/en
Priority to EA200700653A priority patent/EA014852B1/en
Priority to NZ553369A priority patent/NZ553369A/en
Priority to KR1020077008645A priority patent/KR101351771B1/en
Priority to PL05812735T priority patent/PL1809329T3/en
Priority to JP2007532447A priority patent/JP5285275B2/en
Priority to CN200580031485XA priority patent/CN101035562B/en
Publication of WO2006033948A2 publication Critical patent/WO2006033948A2/en
Publication of WO2006033948A3 publication Critical patent/WO2006033948A3/en
Priority to IL181474A priority patent/IL181474A/en
Priority to NO20071914A priority patent/NO342596B1/en
Priority to US11/888,648 priority patent/US8153661B2/en
Priority to HR20120254T priority patent/HRP20120254T1/en
Priority to US13/789,416 priority patent/US8846072B2/en
Priority to US14/464,624 priority patent/US20150111924A1/en
Priority to US15/005,937 priority patent/US20160235726A1/en
Priority to US15/402,011 priority patent/US20170216267A1/en
Priority to US15/870,745 priority patent/US20180256553A1/en
Priority to US16/281,026 priority patent/US20190231762A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Abstract

The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided. Preferably the composition contains bupivacaine and a sugar ester such as saib.
PCT/US2005/032863 2004-09-17 2005-09-15 Sustained local anesthetic composition containing preferably a sugar ester such as saib WO2006033948A2 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
PL05812735T PL1809329T3 (en) 2004-09-17 2005-09-15 Sustained local anesthetic composition containing saib
NZ553369A NZ553369A (en) 2004-09-17 2005-09-15 Sustained local anesthetic composition containing preferably a sugar ester such as saib
DK05812735.8T DK1809329T3 (en) 2004-09-17 2005-09-15 CONTINUOUS LOCAL ANAESTIC COMPOSITION CONTAINING SAIB
CA2581287A CA2581287C (en) 2004-09-17 2005-09-15 Sustained local anesthetic composition containing bupivacaine and saib
ES05812735T ES2378671T3 (en) 2004-09-17 2005-09-15 Prolonged local anesthetic composition containing SAIB
SI200531496T SI1809329T1 (en) 2004-09-17 2005-09-15 Sustained local anesthetic composition containing saib
KR1020137031550A KR101492361B1 (en) 2004-09-17 2005-09-15 Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
RS20120121A RS52198B (en) 2004-09-17 2005-09-15 Sustained local anesthetic composition containing saib
EP05812735A EP1809329B1 (en) 2004-09-17 2005-09-15 Sustained local anesthetic composition containing saib
AT05812735T ATE537844T1 (en) 2004-09-17 2005-09-15 PERMANENT LOCAL ANESTHETIC COMPOSITION WITH SAIB
AU2005287175A AU2005287175B2 (en) 2004-09-17 2005-09-15 Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
MX2007002962A MX2007002962A (en) 2004-09-17 2005-09-15 Sustained local anesthetic composition containing preferably a sugar ester such as saib.
EA200700653A EA014852B1 (en) 2004-09-17 2005-09-15 Controlled delivery system
BRPI0515372A BRPI0515372B8 (en) 2004-09-17 2005-09-15 liquid composition to provide prolonged local anesthesia after administration to an individual, and use of bupivacaine, sucrose acetate isobutyrate and benzyl alcohol
US11/663,125 US8753665B2 (en) 2004-09-17 2005-09-15 Controlled delivery system
KR1020077008645A KR101351771B1 (en) 2004-09-17 2005-09-15 Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
JP2007532447A JP5285275B2 (en) 2004-09-17 2005-09-15 Controlled delivery system
CN200580031485XA CN101035562B (en) 2004-09-17 2005-09-15 Sustained local anesthetic composition containing preferably a sugar ester such as sucrose isobutyl acetate
IL181474A IL181474A (en) 2004-09-17 2007-02-21 Controlled delivery system
NO20071914A NO342596B1 (en) 2004-09-17 2007-04-16 Compositions for persistent local anesthesia comprising bupivacaine as an anesthetic and sucrose acetate obutyrate as a carrier
US11/888,648 US8153661B2 (en) 2004-09-17 2007-07-31 Controlled delivery system
HR20120254T HRP20120254T1 (en) 2004-09-17 2012-03-20 Sustained local anesthetic composition containing saib
US13/789,416 US8846072B2 (en) 2004-09-17 2013-03-07 Controlled delivery system
US14/464,624 US20150111924A1 (en) 2004-09-17 2014-08-20 Controlled Delivery System
US15/005,937 US20160235726A1 (en) 2004-09-17 2016-01-25 Controlled Delivery System
US15/402,011 US20170216267A1 (en) 2004-09-17 2017-01-09 Controlled delivery system
US15/870,745 US20180256553A1 (en) 2004-09-17 2018-01-12 Controlled delivery system
US16/281,026 US20190231762A1 (en) 2004-09-17 2019-02-20 Controlled delivery system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61079704P 2004-09-17 2004-09-17
US60/610,797 2004-09-17
US69139505P 2005-06-17 2005-06-17
US60/691,395 2005-06-17

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US11/663,125 A-371-Of-International US8753665B2 (en) 2004-09-17 2005-09-15 Controlled delivery system
US11/888,648 Continuation US8153661B2 (en) 2004-09-17 2007-07-31 Controlled delivery system
US13/789,416 Continuation US8846072B2 (en) 2004-09-17 2013-03-07 Controlled delivery system

Publications (2)

Publication Number Publication Date
WO2006033948A2 WO2006033948A2 (en) 2006-03-30
WO2006033948A3 true WO2006033948A3 (en) 2006-06-08

Family

ID=35949130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/032863 WO2006033948A2 (en) 2004-09-17 2005-09-15 Sustained local anesthetic composition containing preferably a sugar ester such as saib

Country Status (26)

Country Link
US (9) US8753665B2 (en)
EP (4) EP3103477A1 (en)
JP (2) JP5285275B2 (en)
KR (2) KR101492361B1 (en)
AT (1) ATE537844T1 (en)
AU (1) AU2005287175B2 (en)
BR (1) BRPI0515372B8 (en)
CA (1) CA2581287C (en)
CY (2) CY1112625T1 (en)
DK (3) DK2415484T3 (en)
EA (2) EA014852B1 (en)
ES (3) ES2378671T3 (en)
GE (1) GEP20094831B (en)
HK (1) HK1201437A1 (en)
HR (1) HRP20120254T1 (en)
HU (1) HUE032040T2 (en)
IL (1) IL181474A (en)
LT (1) LT2767292T (en)
MX (1) MX2007002962A (en)
NO (1) NO342596B1 (en)
NZ (1) NZ553369A (en)
PL (2) PL2415484T3 (en)
PT (3) PT1809329E (en)
RS (1) RS52198B (en)
SI (2) SI2415484T1 (en)
WO (1) WO2006033948A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956644B2 (en) 2006-11-03 2015-02-17 Durect Corporation Transdermal delivery systems

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
LT2767292T (en) * 2004-09-17 2016-12-12 Durect Corporation Sustained Local Anesthetic Composition Containing SAIB
EP3173072A1 (en) * 2004-10-01 2017-05-31 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
SI2139457T1 (en) * 2007-03-28 2016-09-30 Innocoll Pharmaceutical Limited A drug delivery device for providing local analgesia, local anesthesia or nerve blockade
US8586103B2 (en) * 2008-02-08 2013-11-19 Foresee Pharmaceuticals, Llc Non-polymeric compositions for controlled drug delivery
US20100143437A1 (en) * 2008-12-09 2010-06-10 Morris Edward J Implantable analgesic
WO2010132673A1 (en) 2009-05-13 2010-11-18 Keraplast Technologies, Ltd. Biopolymer materials
EA026964B1 (en) * 2010-11-24 2017-06-30 Дьюрект Корпорейшн Biodegradable drug delivery composition (embodiments)
ES2689293T3 (en) * 2012-05-16 2018-11-13 Orexa B.V. Means to facilitate food intake and retention
MX352907B (en) * 2013-03-15 2017-12-13 Heron Therapeutics Inc Compositions of a polyorthoester and an aprotic solvent.
RU2703303C2 (en) * 2013-05-24 2019-10-16 Данмаркс Текниске Университет Gel composition for radiation therapy under visual control
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
WO2015123734A1 (en) * 2014-02-21 2015-08-27 The University Of Sydney Liquid carrier materials
EP3509601A1 (en) 2014-04-21 2019-07-17 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
EP3134068B1 (en) 2014-04-21 2021-07-21 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
KR20170025011A (en) 2015-08-27 2017-03-08 고려대학교 산학협력단 Pharmaceutical composition for sustained release of pain-relieving drugs and a device for administration thereof
US20190209538A1 (en) * 2016-05-05 2019-07-11 Liquidia Technologies, Inc. Precision Controlled Load and Release Particles for Post-Operative Pain
CA2972296A1 (en) * 2016-06-30 2017-12-30 Durect Corporation Depot formulations
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
AU2017385977B2 (en) * 2016-12-26 2022-03-17 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
SG11201906132UA (en) * 2017-03-27 2019-10-30 Fruithy Holdings Ltd Insoluble complex or solvate thereof, pharmaceutical composition and use thereof
WO2019071245A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. Implantable depots for controlled release of analgesics to treat postoperative pain associated with orthopedic surgery, and associated devices, systems, and methods
RU2674025C1 (en) * 2017-10-25 2018-12-04 Общество с ограниченной ответственностью "Научно-производственная фирма "ЭЛЕСТ" (ООО "НПФ "ЭЛЕСТ") Drug based on porphyrinic photosensitizer of coproporphyrin for treatment of skin cancer by photodynamic therapy method
WO2021141956A1 (en) * 2020-01-06 2021-07-15 Pacira Pharmaceuticals, Inc, Treatment of pain associated with cesarean section surgery with sustained-release liposomal anesthetic compositions
US20230130180A1 (en) 2020-01-10 2023-04-27 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
EP4087554A4 (en) 2020-01-10 2024-01-17 Pacira Pharmaceuticals Inc Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
BR112022016914A2 (en) * 2020-02-25 2022-10-25 Univ North Carolina Chapel Hill EUTETIC-BASED ANESTHETIC COMPOSITIONS AND THEIR APPLICATIONS
CN116997338A (en) 2021-01-11 2023-11-03 帕西拉制药股份有限公司 Treatment of hip pain with a slow-release liposomal anesthetic composition
CN115068414B (en) * 2021-03-16 2023-07-21 湖南慧泽生物医药科技有限公司 Ropivacaine long-acting solution preparation for injection and preparation method thereof
US11931459B2 (en) 2021-03-19 2024-03-19 Pacira Pharmaceuticals, Inc. Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions
CN115414324A (en) * 2021-05-31 2022-12-02 中国科学院过程工程研究所 Emulsion carrying local anesthetic and preparation method thereof
WO2023147480A1 (en) * 2022-01-28 2023-08-03 Rebel Medicine Inc Pharmaceutical compositions for treating pain
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6426339B1 (en) * 1996-09-16 2002-07-30 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
US20040101557A1 (en) * 1995-06-07 2004-05-27 Gibson John W. High viscosity liquid controlled delivery system and medical or surgical device

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US556450A (en) * 1896-03-17 Antifriction-bearing
US2931802A (en) 1958-04-30 1960-04-05 Eastman Kodak Co Mixed esters of glucose and sucrose
GB1088992A (en) 1963-09-19 1967-10-25 Squibb & Sons Inc Protective dressings
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3743398A (en) 1971-03-22 1973-07-03 Eastman Kodak Co Motion picture projector
NO139560C (en) 1972-04-29 1979-04-04 Takeda Chemical Industries Ltd ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY EFFECTIVE NONAPEPTIDAMIDE DERIVATIVES
DK568274A (en) 1973-11-01 1975-06-23 Wellcome Found
DE2438350C3 (en) 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptides with a strong LH-RH / FSH-RH action, process for their production and pharmaceutical preparations containing them
DE2438352A1 (en) 1974-08-09 1976-02-26 Hoechst Ag PEPTIDE CYCLOPROPYLAMIDE WITH LH-RH / FSHRH EFFECT
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
JPS55154991A (en) 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
NZ194405A (en) 1979-08-02 1982-05-25 Dut Pty Ltd Producing liquid hydrocarbon streams by hydrogenation of fossil-based feedstock
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
DE3716302C2 (en) 1987-05-15 1996-02-01 Henkel Kgaa Improved absorbable bone waxes and their use
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
JPS59210024A (en) 1983-05-13 1984-11-28 Taiyo Kagaku Kk Emulsified tocopherol
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
JPS607418U (en) 1983-06-28 1985-01-19 株式会社デンソー Bearing device with toothed thrust washers
US4891225A (en) 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4630019A (en) 1984-09-28 1986-12-16 Westinghouse Electric Corp. Molded case circuit breaker with calibration adjusting means for a bimetal
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4780320A (en) 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
EP0249347B1 (en) 1986-06-10 1994-06-29 Euroceltique S.A. Controlled release dihydrocodeine composition
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
IT1198449B (en) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5234520A (en) 1987-03-20 1993-08-10 Morgan Adhesives Co. Method of making an adhesive construction
US5391381A (en) 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US4795641A (en) 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4987893A (en) 1988-10-12 1991-01-29 Rochal Industries, Inc. Conformable bandage and coating material
US5324520A (en) 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
IT1240643B (en) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa BIOLOGICALLY ACTIVE PEPTIDES CONTAINING IN 2-ALCHYL TRIPTOFANE CHAIN
US5110685A (en) 1990-05-18 1992-05-05 Exxon Chemical Patents, Inc. Low friction, abrasion resistant polymer coating
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
EP0539559A1 (en) 1991-04-03 1993-05-05 Eastman Kodak Company HIGH DURABILITY MASK FOR DRY ETCHING OF GaAs
JP3313124B2 (en) 1991-07-31 2002-08-12 森下仁丹株式会社 SEAMLESS CAPSULES CONTAINING A HYDROPHILIC SUBSTANCE AND PROCESS FOR PRODUCING THE SAME
US5487898A (en) 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
CA2103163C (en) 1991-08-26 1998-10-20 Mou-Ying Fu Lu Compositions and methods for the sublingual or buccal administration of therapeutic agents
YU87892A (en) 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center INJECTIBLE LONG TERM RELEASE FORMULATIONS AND PROCEDURES FOR THEIR OBTAINING AND USE
IL103275A0 (en) 1991-10-01 1993-02-21 Lilly Co Eli Injectable extended release formulations and methods
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5545408A (en) 1991-10-21 1996-08-13 Peptide Technology Limited Biocompatible implant for the timing of ovulation in mares
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
WO1993010758A1 (en) 1991-12-05 1993-06-10 Pitman-Moore, Inc. A carbohydrate glass matrix for the sustained release of a therapeutic agent
CA2125483A1 (en) 1991-12-11 1993-06-24 Mary Ann Hunter Cetylpyridinium chloride and domiphen bromide in organic solvent
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
AU3941493A (en) 1992-03-30 1993-11-08 Alza Corporation Viscous suspensions of controlled-release drug particles
JP3007687B2 (en) 1992-09-10 2000-02-07 チルドレンズ メディカル センター コーポレイション Biodegradable polymer matrix for sustained delivery of local anesthetics
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
ES2196023T3 (en) 1993-01-06 2003-12-16 Kinerton Ltd IONIC MOLECULAR CONJUGATES OF BIODEGRADABLE POLYESTERS AND BIOACTIVE POLYPEPTIDES.
US5340572A (en) 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
DE69413955T2 (en) 1993-03-17 1999-04-01 Minnesota Mining & Mfg AEROSOL COMPOSITION CONTAINING A DERIVATIVE DERIVATIVE FROM ESTER, AMID OR MERCAPTOESTER
US6042811A (en) 1993-03-17 2000-03-28 3M Innovative Properties Company Aerosol formulation containing a diol-diacid derived dispersing aid
DK44193D0 (en) 1993-04-20 1993-04-20 Euromed I S SPECIAL CONNECTION AND ADMINISTRATIVE TO A SPECIAL CONNECTION OR SIMILAR
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
JP3257750B2 (en) 1993-07-20 2002-02-18 エチコン・インコーポレーテツド Liquid copolymer of ε-caprolactone and lactide
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
JPH07112940A (en) 1993-08-26 1995-05-02 Takeda Chem Ind Ltd Sustained-release parenteral preparation and its production
AU5895994A (en) 1993-10-04 1995-05-01 Mark Chasin Controlled release microspheres
EP0739210B1 (en) 1993-12-29 2002-07-24 Matrix Pharmaceutical, Inc. Compositions for local delivery of cytostatic agents
JP4259610B2 (en) 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド Liquid delivery composition
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
CA2200490C (en) 1994-09-23 2007-01-09 Chiroscience Limited Racemisation and asymmetric transformation processes used in the manufacture of levobupivacaine and analogues thereof
US5599852A (en) 1994-10-18 1997-02-04 Ethicon, Inc. Injectable microdispersions for soft tissue repair and augmentation
DK0788481T3 (en) 1994-10-25 2003-12-01 Darwin Discovery Ltd Process for the preparation of levobupivacaine and analogs thereof
CA2200355C (en) 1994-10-25 2007-03-06 Marianne Langston Crystallisation of levobupivacaine and analogues thereof
GB9501071D0 (en) 1995-01-18 1995-03-08 Chiroscience Ltd Racemisation
US6384227B2 (en) 1995-01-18 2002-05-07 Darwin Discovery Ltd. Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents
BRPI9609033B8 (en) 1995-06-07 2017-04-04 Durect Corp composition and emulsion for the controlled release of a substance.
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
CA2195119C (en) 1995-06-09 2001-09-11 Mark Chasin Formulations and methods for providing prolonged local anesthesia
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
RU2189221C2 (en) 1996-02-02 2002-09-20 Элзэ Копэрейшн Method and device for administering active substance and method for treating prostate carcinoma patients
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
WO1997049391A1 (en) 1996-06-24 1997-12-31 Euro-Celtique, S.A. Methods for providing safe local anesthesia
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
US5747051A (en) 1996-09-27 1998-05-05 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing an amide of a hydroxy fatty acid and a retinoid
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
ES2158611T3 (en) 1996-12-20 2001-09-01 Alza Corp COMPOSITION IN INJECTABLE GEL WITH RETARD EFFECT AND PROCEDURE FOR THE PREPARATION OF SUCH COMPOSITION.
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
DE19714765A1 (en) 1997-04-10 1998-10-15 Merck Patent Gmbh Use of low molecular weight, oligomeric esters of alpha-hydroxy acids and / or aromatic o-hydroxy acids in cosmetic formulations
US5919473A (en) 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6051558A (en) 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
AU737442B2 (en) 1997-07-29 2001-08-16 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
EP1032390B1 (en) 1997-11-19 2003-11-12 Darwin Discovery Limited Anaesthetic formulation
RU2180557C2 (en) * 1998-06-26 2002-03-20 Казахский Государственный национальный университет им. Аль-Фараби Anesthetic composition with prolonged effect
KR20010078754A (en) 1998-06-29 2001-08-21 추후제출 Methods and transdermal compositions for pain relief
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
DE19858891A1 (en) 1998-12-19 2000-06-21 Merck Patent Gmbh Improved bone seals
US6498153B1 (en) 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
JP2003501376A (en) * 1999-06-04 2003-01-14 スカイファーマ インコーポレーテッド Oil core compositions for sustained release of hydrophobic drugs
WO2000078335A1 (en) 1999-06-18 2000-12-28 Southern Biosystems, Inc. COMPOSITIONS FOR CONTROLLED RELEASE OF THE HORMONE GnRH AND ITS ANALOGS
TR200201617T2 (en) * 1999-12-23 2002-10-21 Pfizer Products Inc. Pharmaceutical compositions that provide enhanced drug concentrations
DK1248596T3 (en) 2000-01-11 2007-07-02 Bertex Pharma Gmbh Implants, particles
BR0002246A (en) 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Process for obtaining the enantiomers of racemic bupivacaine, process for obtaining pharmaceutical compositions based on levobupivacaine: pharmaceutical compositions based on levobupivacaine formulated in basic forms or pharmaceutically acceptable salts and use of pharmaceutical compositions based on levobupivacaine formulated in basic forms or pharmaceutically salts acceptable
EP1274459B1 (en) 2000-04-19 2005-11-16 Genentech, Inc. Sustained release formulations comprising growth hormone
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
WO2002010436A2 (en) 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
FR2814308B1 (en) 2000-09-15 2003-03-14 France Telecom METHOD FOR MANAGING THE USE OF A TELECOMMUNICATION LINE AND SYSTEM FOR IMPLEMENTING IT
CN101317825A (en) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 Controlled release hydrocodone formulations
US7318931B2 (en) 2001-06-21 2008-01-15 Genentech, Inc. Sustained release formulation
NZ533435A (en) * 2001-11-14 2007-10-26 Alza Corp Injectable depot compositions and uses thereof
FR2838349B1 (en) 2002-04-15 2004-06-25 Laurence Paris LIQUID COMPOSITIONS FOR SUSTAINED RELEASE SOFT CAPSULES AND PROCESS FOR PRODUCING THE SAME
WO2003101358A1 (en) 2002-05-31 2003-12-11 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20040109893A1 (en) 2002-06-25 2004-06-10 Guohua Chen Sustained release dosage forms of anesthetics for pain management
JP4417039B2 (en) 2002-06-28 2010-02-17 太陽化学株式会社 Oil-in-water emulsion composition
WO2004011032A1 (en) 2002-07-26 2004-02-05 Mikasa Seiyaku Co., Ltd. External preparation
AU2003267788A1 (en) 2002-10-25 2004-05-13 Pfizer Products Inc. Novel injectable depot formulations
AU2003267763A1 (en) 2002-10-25 2004-05-13 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
CA2507522C (en) 2002-12-13 2015-02-24 Durect Corporation Oral drug delivery system
BR0317421A (en) 2002-12-19 2005-11-08 Alza Corp Stable non-aqueous single phase gels and formulations for release from an implantable device
DE10312346A1 (en) 2003-03-20 2004-09-30 Bayer Healthcare Ag Controlled release system
DE10322469A1 (en) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclic compounds
WO2005048742A1 (en) 2003-11-14 2005-06-02 Eastman Chemical Company Sucrose acetate isobutyrate formulation
US20050106304A1 (en) 2003-11-14 2005-05-19 Cook Phillip M. Sucrose acetate isobutyrate formulation
US20050232876A1 (en) 2004-04-19 2005-10-20 Robin Lynn Minga Skin care compositions
WO2005111993A1 (en) 2004-05-14 2005-11-24 Yanmar Co., Ltd. Noise suppressing structure of cabin
US20050266087A1 (en) 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
LT2767292T (en) * 2004-09-17 2016-12-12 Durect Corporation Sustained Local Anesthetic Composition Containing SAIB
EP2361630A1 (en) 2005-02-03 2011-08-31 Intarcia Therapeutics, Inc Implantable drug delivery device comprising particles and an osmotic pump
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
JP5194273B2 (en) 2007-09-20 2013-05-08 三菱電機株式会社 Semiconductor device
SE531980C2 (en) 2008-01-17 2009-09-22 Avtech Sweden Ab Flight control procedure as well as computer programs and computer program product to carry out the procedure

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US20040101557A1 (en) * 1995-06-07 2004-05-27 Gibson John W. High viscosity liquid controlled delivery system and medical or surgical device
US6426339B1 (en) * 1996-09-16 2002-07-30 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"IDdb news focus", CURRENT DRUG DISCOVERY 2004 UNITED KINGDOM, no. NOV., 2004, pages 7 - 10, XP001208384, ISSN: 1472-7463 *
JOHNSON R M ET AL: "Applications of continuous site-directed drug delivery", PROCEEDINGS OF THE WESTERN PHARMACOLOGY SOCIETY 2002 UNITED STATES, vol. 45, 2002, pages 219 - 222, XP009063147, ISSN: 0083-8969 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956644B2 (en) 2006-11-03 2015-02-17 Durect Corporation Transdermal delivery systems

Also Published As

Publication number Publication date
KR101492361B1 (en) 2015-02-11
KR20130136595A (en) 2013-12-12
JP2009073839A (en) 2009-04-09
AU2005287175B2 (en) 2011-12-01
EA200700653A1 (en) 2007-10-26
EP2767292B1 (en) 2016-08-24
CY1118360T1 (en) 2017-06-28
BRPI0515372B8 (en) 2021-05-25
NO20071914L (en) 2007-06-15
CY1112625T1 (en) 2016-02-10
EP1809329A2 (en) 2007-07-25
US8846072B2 (en) 2014-09-30
KR101351771B1 (en) 2014-02-17
CA2581287A1 (en) 2006-03-30
ES2496765T3 (en) 2014-09-19
US8753665B2 (en) 2014-06-17
JP2008513467A (en) 2008-05-01
ES2378671T3 (en) 2012-04-16
IL181474A (en) 2014-05-28
DK2767292T3 (en) 2016-12-19
US20090036490A1 (en) 2009-02-05
US20110009451A1 (en) 2011-01-13
US20170216267A1 (en) 2017-08-03
HRP20120254T1 (en) 2012-04-30
AU2005287175A1 (en) 2006-03-30
US20080167630A1 (en) 2008-07-10
WO2006033948A2 (en) 2006-03-30
PT2767292T (en) 2016-11-23
NO342596B1 (en) 2018-06-18
NZ553369A (en) 2010-11-26
US20180256553A1 (en) 2018-09-13
EP2415484A1 (en) 2012-02-08
GEP20094831B (en) 2009-11-25
JP5285275B2 (en) 2013-09-11
PL2415484T3 (en) 2014-11-28
US20160235726A1 (en) 2016-08-18
LT2767292T (en) 2016-12-12
PL1809329T3 (en) 2012-08-31
EA201001885A1 (en) 2011-12-30
US20190231762A1 (en) 2019-08-01
BRPI0515372B1 (en) 2020-10-06
EP2767292A1 (en) 2014-08-20
MX2007002962A (en) 2008-03-05
PT1809329E (en) 2012-03-29
US8153149B2 (en) 2012-04-10
EP1809329B1 (en) 2011-12-21
EP2415484B1 (en) 2014-06-18
DK1809329T3 (en) 2012-04-02
US20130289069A1 (en) 2013-10-31
CA2581287C (en) 2015-08-25
BRPI0515372A (en) 2008-07-22
SI2415484T1 (en) 2014-10-30
RS52198B (en) 2012-10-31
ATE537844T1 (en) 2012-01-15
EA014852B1 (en) 2011-02-28
HK1201437A1 (en) 2015-09-04
EP3103477A1 (en) 2016-12-14
IL181474A0 (en) 2007-07-04
PT2415484E (en) 2014-09-19
US8153661B2 (en) 2012-04-10
US20150111924A1 (en) 2015-04-23
SI2767292T1 (en) 2017-01-31
DK2415484T3 (en) 2014-09-22
ES2602273T3 (en) 2017-02-20
KR20070059148A (en) 2007-06-11
HUE032040T2 (en) 2017-09-28
JP5285374B2 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
WO2006033948A3 (en) Sustained local anesthetic composition containing preferably a sugar ester such as saib
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
BRPI0508579A (en) compound, pharmaceutical composition, and use of a compound
MY143795A (en) Tetrahydropyridoindole derivatives
WO2004033418A3 (en) Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists
EP2279732A3 (en) Compounds and compositions for delivering active agents
WO2006055752A3 (en) INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME
MXPA05010137A (en) Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists.
WO2006012226A3 (en) N-substituted piperidines and their use as pharmaceuticals
NO20073059L (en) 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2006020598A3 (en) Amido compounds and their use as pharmaceuticals
SG161261A1 (en) Lactam compounds and their use as pharmaceuticals
DK1313510T3 (en) Injectable pharmaceutical composition for systemic administration of pharmacologically active active substances containing medium chain triglycerides
WO2004009549A3 (en) Piperidines useful for the treatment of central nervous system disorders
TW200514772A (en) Novel tetrahydropyridine derivatives
WO2006099187A3 (en) Benzoyl peroxide compositions and methods of use
NO20061395L (en) New pyridine derivatives
WO2006051549A3 (en) Combination therapy associating preferably a ceramide with a cytotoxic drug
TW200621773A (en) Bicyclononene derivatives
WO2004113297A3 (en) Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2005054244A3 (en) Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
WO2006041538A3 (en) A mixture for transdermal delivery of low and high molecular weight compounds
WO2008104975A3 (en) Combination therapy, composition and methods for the treatment of cardiovascular disorders
MX2008001532A (en) Pharmaceutical composition containing indometacin and/or acemetacin.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 553369

Country of ref document: NZ

Ref document number: 181474

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005287175

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/002962

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2005287175

Country of ref document: AU

Date of ref document: 20050915

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007532447

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2005287175

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580031485.X

Country of ref document: CN

Ref document number: 2581287

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2718/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005812735

Country of ref document: EP

Ref document number: 1020077008645

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 9991

Country of ref document: GE

Ref document number: 2007114291

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200700653

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2005812735

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0515372

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 11663125

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: P-2012/0121

Country of ref document: RS